title: An immune competent mouse model for the characterization of recombinant measles vaccines.
abstract: Today, immune compromised interferon-α-receptor deficient mice expressing hCD46 (IFNARCD46tg) are usually used for measles virus (MV) based vaccine characterization. However, for the development of MV-based recombinant vaccine candidates (rMV), an immune competent mouse model is desirable in order to induce and evaluate meaningful immune response. In this study, humoral and cellular immune response induced by rMV in immune competent mice expressing human MV receptor CD46 (hCD46tg) were compared with those induced in wild-type black/6, and IFNARCD46tg mice.   All three strains developed humoral and cellular response against MV, whereas only hCD46tg and IFNARCD46tg mice developed a humoral response against the transgene. Differences were observed in the magnitude of the response, where the IFNARCD46tg mice displayed the strongest immune responses, followed by the hCD46tg mice and the black/6 mice. Interestingly, hCD46tg and wt black/6 mice showed a predominant CD4(+) T-cell response against MV-N, whereas IFNARCD46tg mice developed both, CD4(+) and CD8(+) T-cell response against MV-N. Analysis of the cytokine profile of MV-N specific CD4(+) T-cells and transgene (SIVgag) specific CD8(+) T-cells revealed qualitative differences of the T-cell responses; noticeably a significant reduction of the frequency of CD4(+)IL-2(+) expressing cells in IFNARCD46tg mice as compared with hCD46tg or wt black/6 mice. We show in this study significant quantitative and qualitative differences in immune responses between immune competent and immune-compromised mice. Our results therefore highlight the importance of the animal model and support the use of hCD46tg mice as mouse model for the characterization of the immunological profile induced by recombinant measles virus vaccine candidates.
authors.affiliation: a Crucell-Switzerland AG; Bern, Switzerland.
authors.forename: René R
authors.initials: RR
authors.lastname: Marty
authors.forename: Marlyse C
authors.initials: MC
authors.lastname: Knuchel
authors.forename: Teldja Neige Azzouz
authors.initials: TN
authors.lastname: Morin
authors.forename: Hussein Y
authors.initials: HY
authors.lastname: Naim
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D016207:Cytokines / Q000378:metabolism; D005260:Female; D015870:Gene Expression; D008297:Male; D008457:Measles / Q000276:immunology / Q000517:prevention & control; D008458:Measles Vaccine / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D008459:Measles virus / Q000235:genetics / Q000276:immunology*; D051916:Membrane Cofactor Protein / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D023421:Models, Animal; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; C497857:CD46 protein, human; D016207:Cytokines; D008458:Measles Vaccine; D051916:Membrane Cofactor Protein; D014614:Vaccines, Synthetic
keywords: CD46; cellular immunity; humoral immunity; measles virus; mouse model; recombinant vaccine